Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

Frisoni, Giovanni B. and Boccardi, Marina and Barkhof, Frederik and Blennow, Kaj and Cappa, Stefano and Chiotis, Konstantinos and Démonet, Jean-Francois and Garibotto, Valentina and Giannakopoulos, Panteleimon and Gietl, Anton and Hansson, Oskar and Herholz, Karl and Jack, Clifford R. and Nobili, Flavio and Nordberg, Agneta and Snyder, Heather M. and Ten Kate, Mara and Varrone, Andrea and Albanese, Emiliano and Becker, Stefanie and Bossuyt, Patrick and Carrillo, Maria C. and Cerami, Chiara and Dubois, Bruno and Gallo, Valentina and Giacobini, Ezio and Gold, Gabriel and Hurst, Samia and Lönneborg, Anders and Lovblad, Karl-Olof and Mattsson, Niklas and Molinuevo, José-Luis and Monsch, Andreas U. and Mosimann, Urs and Padovani, Alessandro and Picco, Agnese and Porteri, Corinna and Ratib, Osman and Saint-Aubert, Laure and Scerri, Charles and Scheltens, Philip and Schott, Jonathan M. and Sonni, Ida and Teipel, Stefan and Vineis, Paolo and Visser, Pieter Jelle and Yasui, Yutaka and Winblad, Bengt. (2017) Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. The Lancet neurology, 16 (8). pp. 661-676.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/66744/

Downloads: Statistics Overview


The diagnosis of Alzheimer's disease can be improved by the use of biological measures. Biomarkers of functional impairment, neuronal loss, and protein deposition that can be assessed by neuroimaging (ie, MRI and PET) or CSF analysis are increasingly being used to diagnose Alzheimer's disease in research studies and specialist clinical settings. However, the validation of the clinical usefulness of these biomarkers is incomplete, and that is hampering reimbursement for these tests by health insurance providers, their widespread clinical implementation, and improvements in quality of health care. We have developed a strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers. Sufficient evidence of analytical validity (phase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their clinical validity (phases 2 and 3) and clinical utility (phases 4 and 5) are incomplete. To complete these phases, research priorities include the standardisation of the readout of these assays and thresholds for normality, the evaluation of their performance in detecting early disease, the development of diagnostic algorithms comprising combinations of biomarkers, and the development of clinical guidelines for the use of biomarkers in qualified memory clinics.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Geriatrie > Geriatrie (Kressig)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Geriatrie > Geriatrie (Kressig)
07 Faculty of Psychology > Departement Psychologie
07 Faculty of Psychology > Departement Psychologie > Ehemalige Einheiten Psychologie > Molecular Neuroscience (Papassotiropoulos)
UniBasel Contributors:Monsch, Andreas U. U
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:06 Feb 2019 14:15
Deposited On:06 Feb 2019 14:15

Repository Staff Only: item control page